Akari Therapeutics Plc (AKTX)


Stock Price Forecast

May 22, 2020


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Akari Therapeutics Plc chart...

About the Company

Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor. The company was founded on October 7, 2004 and is headquartered in London, the United Kingdom.

Sector

Health Technology

Industry

Pharmaceuticals: Major

Employees

10

CEO

Clive Stuart Richardson

Exchange

NASDAQ

Website

http://akaritx.com

$M

Total Revenue

10

Employees

$36M

Market Capitalization

-2.01

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $AKTX News

Akari Therapeutics, Plc (AKTX)

3d ago, source: Yahoo Finance

*Close price adjusted for splits.**Adjusted close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...

Akari Therapeutics PLC ADR

1y ago, source: Barron's

Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases.

Geriatric Medicines Market Size Future Scope, Demands and Projected Industry Growths 2023- 2033

20d ago, source:

The geriatric medicines market studied was anticipated to witness a CAGR of nearly 6.5% during the forecast period.

Latest Press Releases

9d ago, source: Seeking Alpha

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser. Is this happening to you frequently? Please report it on our ...

Propulsion of Asthma Pipeline as Novel and Extensive 95+ Therapies Likely to Enter in the Treatment Domain | DelveInsight

20d ago, source:

DelveInsight's 'Asthma Pipeline Insight - 2023'report provides comprehensive global coverage of available, marketed, and pipeline asthma therapies in various stages of clinical development, major ...

Akari Therapeutics PLC ADR

26d ago, source: Wall Street Journal

1 Day AKTX 4.82% DJIA -1.02% Russell 2K -0.92% Health Care/Life Sciences -0.05% ...

Akari Therapeutics, Plc (AKTX)

2d ago, source: Yahoo Finance

*Close price adjusted for splits.**Close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...

Akari Therapeutics PLC ADR

7d ago, source: Wall Street Journal

1 Day AKTX -10.88% DJIA -2.04% Russell 2K -3.21% Health Care/Life Sciences 1.29% ...

Akari Therapeutics, Plc (AKTX)

2mon ago, source: Yahoo Finance

Overall score is calculated based on proprietary scores based on sector averages in key company indicators: fair value, dividends, innovation, hiring, and insider sentiment. Note: if you don't see ...

Akari Therapeutics plc ADS (AKTX)

3y ago, source: Nasdaq

Nasdaq Official Closing Price (NOCP)" is a process for identifying the Nasdaq market-specific closing price for Nasdaq-listed issues. Data provided by Nasdaq Data Link, a premier source for ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...